

## Special Issue

# Rare Cancers, Diagnostic Challenges and Personalized Therapeutic Approaches in the 21st Century

### Message from the Guest Editors

Rare cancers, as defined by the National Cancer Institute in the US, have an incidence of less than 15 cases per 100,000 people per annum. They comprise about 200 cancer types, and nearly one-fourth of all new cancer cases in the US are rare. Because of low case counts, studying rare cancers represents a challenge. This is reflected in a limited understanding of their biology, challenges with diagnosis and classification, non-uniform standards of care, and generally poor outcomes. Personalized therapeutic approaches, based on advances in cancer biology and novel markers, are yielding promising changes to this landscape. In this Special Issue, we invite researchers to submit original research manuscripts and reviews on diagnostic challenges, advances in cancer biology, and novel therapeutic approaches to rare cancers.

---

### Guest Editors

Dr. Jason Roszik

Dr. Asad Ullah

Dr. Nabin Raj Karki

---

### Deadline for manuscript submissions

closed (20 February 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/194890](https://mdpi.com/si/194890)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)